The article presents the results of the analysis of clinical and laboratory parameters in 158 patients with chronic heart failure (CHF) depending on the eGFR level. The patients were divided into four groups. A statistically significant correlation was established between a decrease in eGFR and an increase in the level of congestion markers (CA125), uric acid, phosphorus, iPTH, as well as the frequency of albuminuria. Changes in hemodynamic parameters and nutritional status were also identified, reflecting the progression of heart and kidney failure
The article presents the results of the analysis of clinical and laboratory parameters in 158 patients with chronic heart failure (CHF) depending on the eGFR level. The patients were divided into four groups. A statistically significant correlation was established between a decrease in eGFR and an increase in the level of congestion markers (CA125), uric acid, phosphorus, iPTH, as well as the frequency of albuminuria. Changes in hemodynamic parameters and nutritional status were also identified, reflecting the progression of heart and kidney failure
| № | Author name | position | Name of organisation |
|---|---|---|---|
| 1 | Khudoyberdiyeva G.A. | ! | Tashkent State Medical University |
| 2 | Raimkulova N.R. | ! | ! |
| № | Name of reference |
|---|---|
| 1 | 1.Zannad F., Ferreira J.P., Pocock S.J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2021;385 (20):1883-1893.2.McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med.2019;381 (21):1995-2008.3.Filippatos G., Anker S.D., Böhm M. et al. Empagliflozin and serum CA125 in patients with heart failure: a biomarker analysis from the EMPEROR-Reduced trial. Eur J Heart Fail.2022;24 (3):514-524.4.Nunuez J., Miñana G., Bodí V. et al. Clinical utility of CA125 measurement in heart failure. Heart Fail Rev. 2020;25 (3):371-382.5.Heerspink H.J.L., StefánssonB.V., Correa-Rotter R. et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383 (15):1436-1446.6.Malishev Yu.I., Tsymbalyuk A.F., Kalinin N.V. CA125 as a marker of systemic congestion in CHF: new horizons. Cardiology.2021;61 (5):67-73.7.Thomas M.C., Cooper M.E., Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol.2021;17 (4):220-232.8.McCullough P.A., ÖNeill W.W. Risk Prediction in Heart Failure and Kidney Disease: Biomarkers and Beyond. Rev Cardiovasc Med.2020;21 (4):531-543.9.Vereshchagin I.V., Semenov A.L., Krivchenko A.I. et al. Chronic heart failure and chronic kidney disease: clinical aspects of interaction. Therapeutic Archive.2020;92 (9):115-121.10.Bakris G.L., Agarwal R., Anker S.D. et al. Effect of finerenone on the outcome of chronic kidney disease in type 2 diabetes. N Engl J Med. 2020;383 (23):2219-2229. |